Response to Therapy in Patients With Amyloidosis: A Prospective Study and Survivors for 10 Years or More
| Factor . | Melphalan + Prednisone2 (n = 148) . | 10-Yr Survivors (n = 19) . | ||
|---|---|---|---|---|
| No.3-150 . | % . | No.3-150 . | % . | |
| Serum albumin | 13/84 | 15 | 2/7 | 29 |
| Serum monoclonal protein | 21/104 | 20 | 3/10 | 30 |
| Urinary monoclonal protein | 19/99 | 19 | 9/11 | 82 |
| Urinary total protein | 12/68 | 18 | 3/7 | 43 |
| Total no. of patients with protein responses | 42/148 | 28 | 10/19 | 53 |
| Factor . | Melphalan + Prednisone2 (n = 148) . | 10-Yr Survivors (n = 19) . | ||
|---|---|---|---|---|
| No.3-150 . | % . | No.3-150 . | % . | |
| Serum albumin | 13/84 | 15 | 2/7 | 29 |
| Serum monoclonal protein | 21/104 | 20 | 3/10 | 30 |
| Urinary monoclonal protein | 19/99 | 19 | 9/11 | 82 |
| Urinary total protein | 12/68 | 18 | 3/7 | 43 |
| Total no. of patients with protein responses | 42/148 | 28 | 10/19 | 53 |
Number of patients with response to therapy/number with abnormal value. A response was defined as one or more of the following: (1) an increase of 1 g or more in the serum albumin value, given an initial value of less than 3 g/dL and stable renal function; (2) disappearance of or a reduction of at least 50% in the serum monoclonal protein concentration, given an initial value of at least 1 g/dL; (3) disappearance of or a reduction of at least 50% in the urinary monoclonal protein concentration, given an initial value of at least 0.5 g/24 h; and (4) a reduction of at least 50% in the urinary protein concentration, given an initial value of at least 3 g/24 h in the absence of progressive renal failure.